BioCryst Pharmaceuticals, Inc. (BCRX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BCRX Revenue Growth
Revenue Breakdown (FY 2025)
BCRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
BCRX Revenue Analysis (2014–2025)
As of May 8, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) generated trailing twelve-month (TTM) revenue of $885.7 million, reflecting solid growth of +7.5% year-over-year. The most recent quarter (Q1 2026) recorded $156.4 million in revenue, down 61.5% sequentially.
Looking at the longer-term picture, BCRX's 5-year compound annual growth rate (CAGR) stands at +117.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $874.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows BCRX's business is primarily driven by Product (71%), License (28%), and Collaborative And Other Research And Development (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY), BCRX has underperformed the peer group in terms of revenue growth. Compare BCRX vs RARE →
BCRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCRXCurrent | $886M | +7.5% | +117.9% | 39.0% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
BCRX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $874.8M | +94.1% | $855.8M | 97.8% | $341.0M | 39.0% |
| 2024 | $450.7M | +36.0% | $438.2M | 97.2% | $-2,543,000 | -0.6% |
| 2023 | $331.4M | +22.4% | $326.8M | 98.6% | $-103,709,000 | -31.3% |
| 2022 | $270.8M | +72.3% | $264.2M | 97.6% | $-148,435,000 | -54.8% |
| 2021 | $157.2M | +782.4% | $149.9M | 95.4% | $-177,720,000 | -113.1% |
| 2020 | $17.8M | -63.5% | $16.1M | 90.6% | $-174,757,000 | -981.1% |
| 2019 | $48.8M | +136.5% | $44.7M | 91.6% | $-99,455,000 | -203.7% |
| 2018 | $20.7M | -18.0% | $20.2M | 97.7% | $-94,220,000 | -456.2% |
| 2017 | $25.2M | -4.4% | $23.5M | 93.2% | $-57,411,000 | -227.9% |
| 2016 | $26.4M | -45.4% | $23.7M | 89.8% | $-48,607,000 | -184.4% |
See BCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
Is BCRX's revenue growth accelerating or slowing?
BCRX maintains +7.5% revenue growth, in line with its 5-year CAGR of +117.9%. TTM revenue stands at $886M. Growth rate remains consistent with historical average.
What is BCRX's long-term revenue growth rate?
BioCryst Pharmaceuticals, Inc.'s 5-year revenue CAGR of +117.9% reflects the sustained expansion pattern. Current YoY growth of +7.5% is near this long-term average.
How is BCRX's revenue distributed by segment?
BCRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.